A 12-month open-label evaluation of the long-term safety of DVS-233 [desvenlafaxine] SR [sustained release] in outpatients with major depressive disorder.

Trial Profile

A 12-month open-label evaluation of the long-term safety of DVS-233 [desvenlafaxine] SR [sustained release] in outpatients with major depressive disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 06 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top